........................................................................ 27
.......................................................................... 30
.............................................................................. 31
NOODOPROEPEN ..................................................................... 34
......................................................................... 35
........................................................................... 37
.................................................................................. 38
-
(TOT) ............................................................... 39
...................................................................... 39
........................................................................... 43
N-iv
) ................................................. 26
..................................................................... 29
..................................................................... 29
.................................................................. 30
..................................................................... 30
.......................................................... 31
.................................................................. 31
........................................................... 35
............................................................. 36
.................................................................. 37
(BCL) .................................................... 39
.............................................................. 40
............................................................ 40
..................................................................... 41
............................................ 38
........................................... 40